Folate-Cyclodextrin Conjugate for Targeted Chemotherapy
March 2021
in “
Arrow - TU Dublin (Technological University Dublin)
”
Studysummary This study tested a folate-conjugate drug delivery system and found its cytotoxicity depends on whether the treated cells overexpress folate receptors, suggesting potential for targeted chemotherapy.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study explored the development of a folate-cyclodextrin conjugate (CDEnFA) as a targeted drug delivery system for chemotherapy, aiming to reduce side effects like hair loss by specifically targeting cancer cells. The conjugate was tested for cytotoxicity on folate over-expressing HeLa cells and folate receptor-deficient A549 cells, with EC50 values compared to the standard chemotherapy drug, Cisplatin. This approach aimed to improve the selectivity of anticancer drugs, potentially minimizing damage to healthy cells.
